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Introduction: Preeclampsia is a heterogeneous gestational disease characterized by maternal 
hypertension and proteinuria, affecting 2-7% of pregnancies. The disorder is initiated by 
insufficient placental development, but studies characterizing the placental disease 
components are lacking. Methods: Our aim was to phenotype the preeclamptic placenta using 
high-resolution magic angle spinning nuclear magnetic resonance spectroscopy (HR-MAS 
MRS). Placental samples collected after delivery from women with preeclampsia (n=19) and 
normotensive pregnancies (n=15) were analyzed for metabolic biomarkers including amino 
acids, osmolytes, and components of the energy and phospholipid metabolism. The metabolic 
biomarkers were correlated to clinical characteristics and inflammatory biomarkers in the 
maternal sera. Results: Principal component analysis showed inherent differences in placental 
metabolic profiles between preeclamptic and normotensive pregnancies. Significant 
differences in metabolic profiles were found between placentas from severe and non-severe 
preeclampsia, but not between preeclamptic pregnancies with fetal growth restricted versus 
normal weight neonates. The placental metabolites correlated with the placental stress marker 
sFlt-1 and triglycerides in maternal serum, suggesting variation in placental stress signaling 
between different placental phenotypes. Discussion: HR-MAS MRS is a sensitive method for 
defining the placental disease component of preeclampsia, identifying several altered 
metabolic pathways. Placental HR-MAS MRS analysis may improve insight into processes 
affected in the preeclamptic placenta, and represents a novel long-required tool for a sensitive 
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Introduction  4 
Preeclampsia is a gestational disease that originates in the placenta and affects 2-7% of 5 
pregnancies [1]. Preeclampsia may reflect an excessive maternal inflammatory response to 6 
insufficient placentation or to pregnancy itself [2, 3]. The current hypothesis in regard to its 7 
development states that the uterine spiral arteries develop insufficiently during placentation, 8 
causing placental ischaemia and abnormal inflammation as the pregnancy develops [1, 4]. The 9 
oxidatively stressed placenta releases increasing amounts of inflammatory and angiogenic 10 
factors to the maternal circulation, eventually causing the manifestations of preeclampsia; 11 
endothelial dysfunction, intravascular inflammation and activation of the hemostatic systems 12 
clinically evidenced by proteinuria and hypertension [1, 4] .  13 
Preeclampsia is a heterogeneous disease, and markers in the placenta identifying disease 14 
subgroups are scarce [5]. Common subtypes of preeclampsia are today defined by clinical 15 
characteristics such as severity of maternal features, time of diagnosis, and presence of fetal 16 
growth restriction (FGR) [6, 7]. These subgroups are based on end stage maternal or fetal 17 
factors, and placental histology findings and maternal serum markers overlap between groups 18 
[2]. Similar end stage presentations of preeclampsia may stem from different pathologic 19 
placental processes [8]. Studying the altered metabolism of the placenta in preeclampsia, and 20 
how it is affected with disease severity and when combined with FGR, may give insight into 21 
which processes are shared and specific for these disorders. Placental phenotyping by 22 




Metabolite expression is the final level of regulation over gene and protein expression, and 24 
can be measured directly in tissue samples using high resolution magic angle spinning 25 
magnetic resonance spectroscopy (HR-MAS MRS) [9]. HR-MAS MRS has been used 26 
successfully in investigating molecular subtypes of breast cancer for improved treatment and 27 
outcome stratification [10]. HR-MAS MRS of intact placental tissue from normal or 28 
preeclamptic pregnancies has not been performed previously.  29 
Our aim is to identify differences in placental metabolic expression between normotensive 30 
and preeclamptic pregnancies using HR-MAS MRS metabolomics. We further aim to 31 
investigate whether the placental metabolites correlate to maternal serum measurements of 32 
placental stress and inflammatory markers. We hypothesize that placental metabolic profiling 33 
provides a sensitive method for detailed identification of the placental component of 34 
preeclampsia. 35 




Materials & Methods 37 
Study participants, serum samples and placental tissue biopsies 38 
The study was approved by the Norwegian Regional Committee for Medical and Health 39 
Research Ethics (REC 2012/1040) and informed consent was obtained from all participants. 40 
Women with singleton pregnancies delivering by cesarean section (CS) were recruited at 41 
Haukeland University Hospital (Bergen, Norway) from 2009 to 2012. Women with 42 
pregnancies complicated by preeclampsia were included as cases. Healthy pregnant women 43 
with no previous history of pregnancies with preeclampsia or FGR were included as 44 
normotensive controls. Preeclampsia was defined as persistent hypertension (systolic/diastolic 45 
blood pressure 140/90 mmHg) plus proteinuria (≥0.3g/24h or ≥1+ by dipstick) developing 46 
after 20 weeks of gestation [6]. Superimposed preeclampsia was defined as pre-existing 47 
hypertension where the women developed proteinuria after 20 weeks of gestation [6] and was 48 
included in the preeclampsia group. Preeclampsia was sub-classified as severe if diagnosed 49 
with one or more of the severe features: hypertension ≥160/110mmHg, proteinuria ≥3 g/24 h, 50 
pulmonary symptoms, seizures/eclampsia, oliguria of <500mL/24 h, or central nervous 51 
system symptoms [7]. Preeclamptic women not meeting the criteria for severe preeclampsia 52 
were designated as non-severe. FGR was diagnosed by serial ultrasound measurements 53 
showing reduced intrauterine growth defined as an estimated fetal weight gain between 54 
ultrasound examinations below the 10th percentile [11, 12]. In absence of serial ultrasound 55 
measurements, neonates were defined with FGR if their birth weights were below the 5th 56 
percentile for gestational age (GA) according to Norwegian fetal weight reference curves 57 
[13]. In the FGR subgroup in the study cohort, one pregnancy was defined as FGR based on 58 
SGA criteria alone, while two pregnancies had FGR diagnoses but with neonatal birth weights 59 




A complete overview of clinical characteristics of the pregnancies studied are available in the 61 
Supplementary Tab. S.1 and S.2 [14]. 62 
Women with gestational hypertension, HELLP syndrome, or pregnancies with fetal 63 
chromosomal or congenital abnormalities were not included in the study. The primary 64 
indication for CS for the cases was preeclampsia, while indications for the normotensive 65 
women included breech presentation, previous CS or maternal request. None of the 66 
participants experienced signs or symptoms of labor. Clinical information was collected from 67 
the medical journals and through interviews.  68 
Maternal venous blood was collected prior to CS, left to clot for ≤30 minutes, centrifuged at 69 
1800G for 10 minutes, and serum aliquots (1mL) were stored at -80oC until analysis. A 70 
tangential section (100 mg) from the maternal central side of the placenta was collected after 71 
delivery, placed in a cryotube and frozen either in liquid nitrogen or directly at -80oC within 72 
101 ± 49 minutes (mean ± SD) after delivery. The tissue was collected at a maximum depth of 73 
0.5 cm and did not include the chorionic plate, but consisted of tissue from the basal plate and 74 
intervillous space, including placental parenchyma. Visible blood clots were carefully 75 
removed. Sample processing times were not significantly different between the preeclamptic 76 
and normotensive groups. 77 
Maternal serum analyses 78 
Soluble fms-like tyrosine kinase receptor 1 (sFlt-1) was measured in duplicate using a 79 
quantitative sandwich ELISA according to the manufacturer’s instructions (#DVR100B, R&D 80 
Systems, Abingdon, UK). High sensitivity C-reactive protein (hs-CRP) (turbidimetric assay, 81 
Modular P analyzer, Roche, Burgess Hill, UK), total cholesterol, high-density lipoprotein 82 




measured by accredited methods at the Department of Clinical Chemistry, St. Olavs Hospital, 84 
Trondheim, Norway.  85 
HR-MAS MRS placental analyses 86 
The placental biopsies were analyzed in random order, blinded to pregnancy outcome. 87 
Samples were prepared on a metal plate cooled in liquid nitrogen in order to minimize the 88 
effect of tissue degradation, as described in [15, 16]. Biopsies (7.5 ± 1.4 mg) were cut to fit 89 
30µL disposable inserts (Bruker Biospin Corp, USA) filled with 3µL D2O containing 25mM 90 
formate for shimming. Spin-echo spectra were acquired on a Bruker Avance DRX600 91 
spectrometer with a 1H/13C MAS probe with gradient (Bruker Biospin GmbH, Germany) 92 
using the following parameters: 5KHz spin rate, 5°C probe temperature, cpmgpr1d pulse 93 
sequence (Bruker Biospin) with 78ms total echo time, spectral width of 20 ppm and 256 94 
scans. Two samples were additionally analyzed by 13C-1H spectroscopy (HSQC, HMBC) for 95 
aid in metabolite identification.  96 
Data analysis 97 
Spectra were Fourier transformed into 65.5k points following 0.3 Hz line broadening, and 98 
automatically phased and baseline corrected (Topspin 3.1, Bruker Biospin). The spectra were 99 
restricted to the region 0.5 to 4.7 ppm, peak aligned using iCoshift to correct for slight 100 
variations in peak positions [17], and divided by the total area under the spectrum curve to 101 
account for variation in sample weight. Metabolites were identified by comparing chemical 102 
shift values to spectral databases [18] and correlation of metabolite peaks using Statistical 103 
Total Correlation Spectroscopy [19]. Semi-quantitative metabolite levels were measured by 104 
integrating the spectral regions of identified metabolites (Matlab r2013b, The Mathworks Inc., 105 
Natick, MA, USA). The concentrations of the metabolites are given in arbitrary units, but 106 




sample. The normalized metabolite data are available as a supplementary file (Supplementary 108 
Table S.7). 109 
Multivariate analysis was performed in PLS Toolbox 7.3.1 (Eigenvector Research Inc., WA, 110 
USA), and with MetaboAnalyst [20]. Quantified metabolite levels were autoscaled before 111 
multivariate modeling. The metabolic profiles were evaluated by principal component 112 
analysis (PCA) for initial data exploration [21]. Partial least squares discriminant analysis 113 
(PLS-DA) discriminated metabolic features between subgroups of preeclampsia (presence of 114 
severe maternal features or FGR), and between normotensive and preeclamptic pregnancies. 115 
Eight preeclamptic women had both FGR neonates and severe preeclampsia features, and 116 
these were included both in the FGR group and the severe preeclampsia group in subgroup 117 
analyses. The performance of the PLS-DA models was evaluated by five-fold cross-validation 118 
which was repeated twenty times. The number of latent variables was chosen as the number 119 
giving the highest accuracy of classification. Sensitivity, specificity and classification 120 
accuracy were reported as averages from the validation set for each model. To evaluate the 121 
validity of the regression and classification results, 1000 permutation tests were performed 122 
with models considered valid at p≤0.05. In permutation testing, classes or dependent values 123 
are shuffled and models built on the random data [22]. The classification results from the true 124 
model should then be outside the 95% confidence limit for the permuted models to be 125 
considered valid.  126 
Univariate statistical analyses were performed in SPSS v. 20 (SPSS, Chicago, IL). Clinical 127 
characteristics were compared between disease subgroups using the one-way ANOVA with 128 
Tukey post-hoc test for groupwise normally distributed data (GA, birth weight) or the Kruskal 129 
Wallis test with post-hoc pairwise Mann-Whitney U tests for nonparametric data (maternal 130 




for categorical variables. Metabolite levels and serum measurements were compared using the 132 
Mann-Whitney U test. False discovery rate correction for multiple testing (Benjamini-133 
Hochberg) was applied [23]. To adjust for confounding effects of GA, linear regression 134 
models with log-transformed metabolites as dependent variable and preeclampsia and GA as 135 
independent variables were generated. Interaction terms between preeclampsia and covariates 136 
were included in the models if significant, otherwise excluded. Standardized residuals were 137 
assessed with the Kolmogorov Smirnov test. Quantitative metabolite set enrichment analysis 138 
(MSEA) was performed for inferring the metabolic pathways associated with disease [24].  139 
Results  140 
Clinical characteristics  141 
The clinical characteristics of the study participants are described in Tab. 1. A total of 34 142 
pregnant women were included in the study (preeclampsia; n=19 and normotensive; n=15). 143 
Birth weight and GA were lower in women with preeclampsia than in normotensive 144 
pregnancies, and preeclamptic women were more likely to be primiparous. Maternal serum 145 
levels of creatinine, uric acid and sFlt-1 were significantly higher before delivery in women 146 
with preeclampsia compared to normotensive women (Tab. 2). 147 
HR-MAS analyses 148 
In total 25 metabolites were identified in the HR-MAS MRS analysis of placental biopsies 149 
(Supplementary Tab. S.3). The metabolite levels are shown in Tab. 2, grouped by metabolic 150 
pathway [25]. Median spectra from placental biopsies from normotensive and preeclamptic 151 
pregnancies are shown in Fig. 1.  152 




The results from PCA are shown in Fig. 2. The score plots show the between-samples 154 
variation and are colored by ellipses of 95% confidence intervals for preeclampsia subgroups 155 
defined by presence or absence of preeclampsia (Fig. 2A), severe or non-severe preeclampsia 156 
(Fig. 2B) or preeclampsia with or without FGR (Fig. 2C). Superimposed preeclampsia 157 
appeared in the overlapping region in the score plot between preeclampsia and normal 158 
pregnancy (Fig. 2A). Normotensive pregnancies were clearly different from preeclamptic 159 
pregnancies in placental metabolic expression profile. The preeclamptic pregnancies showed a 160 
more heterogeneous metabolic expression than the more unified group of normotensive 161 
pregnancies (Fig. 2A). Placentas from preeclamptic pregnancies showed enrichment of 162 
phospholipid biosynthesis and depletions in bile acid biosynthesis, taurine metabolism, 163 
ammonia and urea cycles and protein biosynthesis, compared to placentas from normotensive 164 
pregnancies (Supplementary Tab. S.4). No effect of fetal sex, maternal age or body mass 165 
index on the placental metabolic profiles was found using PLS-DA. 166 
The preeclampsia subgroups defined by severe preeclampsia or FGR had overlapping 167 
metabolic expressions (Fig. 2B and C). The severe preeclampsia placental profiles were more 168 
similar to the normotensive profiles than preeclampsia without severe features (Fig. 2B). In 169 
contrast, placental metabolic profiles of preeclampsia with FGR were more separated from 170 
normotensive profiles than preeclampsia without FGR (Fig. 2C). The loading plot (Fig. 2D) 171 
identified the metabolites contributing to the sample distributions. The first principal 172 
component (PC1) showed an increase in aspartate, phosphocholine and 173 
glycerophosphocholine and decrease in glutamate, taurine, ascorbate and glutamine 174 
corresponding to a preeclamptic phenotype. The second PC (PC2) showed variation not 175 
related to group separation: relative to samples with low scores on PC2, samples with high 176 
scores on PC2 had increased phosphocholine, glycerophosphocholine, myo-inositol and 177 




PLS-DA defined metabolic profiles for preeclampsia and its subgroups (Tab. 3). A significant 179 
difference in placental metabolic profiles was found between preeclamptic and normotensive 180 
pregnancies, and between placentas from severe and non-severe preeclampsia. There was no 181 
significant difference in the metabolic profiles between preeclampsia with or without FGR. 182 
Receiver-operator characteristic curves for the predictions, and results from the permutation 183 
tests, are shown in Supplementary Figure S.1. PLS regression revealed correlations between 184 
the placental metabolic profiles and maternal serum markers; triglycerides, sFlt-1, uric acid, 185 
and creatinine (Tab. 4). Serum sFlt-1 showed the highest correlation to placental metabolites 186 
(R2=0.49, p<0.001). Of special interest, maternal serum sFlt-1 was clearly correlated with 187 
increased placental glycerophosphocholine levels, and decreased glutamate, taurine, 188 
glutamine, valine and ethanolamine. 189 
Twelve out of 25 metabolites were significantly different between the placentas from 190 
preeclamptic and normotensive pregnancies after correction for multiple testing (Tab. 2). 191 
Placental levels of choline and lysine were increased in severe preeclampsia (Supplementary 192 
Tab. S.5). Linear regression modeling of the placental metabolites differing between 193 
preeclamptic and normotensive pregnancies revealed that GA significantly affected only the 194 
levels of ethanolamine and glycine (increasing with GA). Glutamine, glutamate, taurine, 195 
valine, 3-hydroxybutyrate and ascorbate remained significantly different between 196 
preeclamptic and normotensive groups after correction for GA (Supplementary information, 197 
Tab. S.6).  198 
Discussion 199 
We have for the first time uncovered metabolic profiles of placental tissue using HR-MAS 200 
MRS technology, reporting a novel method for defining the placental disease component in 201 




state in preeclampsia compared to normotensive pregnancies. Our study demonstrated 203 
metabolic differences between severe and non-severe preeclampsia, and showed that the 204 
presence of FGR was not reflected in the placental metabolites. The metabolic placenta 205 
profile correlated with maternal serum markers for angiogenic imbalance, uric acid and lipid 206 
levels. This is the largest metabolic profiling of placental tissue from preeclamptic 207 
pregnancies published to date. 208 
Our study uses a novel technique in placental analyses to expand upon previous metabolomic 209 
studies on placental explants and cell culture from preeclamptic pregnancies [26-28]. 210 
Metabolic profiling of whole placental tissue by HR-MAS MRS is a nondestructive analysis 211 
allowing further proteomic or genomic analysis of the same sample. Studies in cancer have 212 
found metabolic profiles to correlate to prognostic factors and survival [29]. We have shown 213 
placental metabolites correlating with the disease severity and with maternal serum factors 214 
reflecting the placental disease. The scattering of the metabolic placental profiles in 215 
preeclampsia compared to normotensive placentas clearly reflected that preeclampsia is a 216 
heterogeneous disease and indicates that several different pathologic processes in the placenta 217 
may underlie similar clinical signs in the mother. This holistic approach may provide a 218 
sensitive classification of the placental component of preeclampsia. This method provides a 219 
novel tool for understanding the underlying placental disease mechanisms, and thereby 220 
phenotyping the disease based on placental involvement, not only end stage maternal and fetal 221 
features. The findings warrant further investigation in a larger cohort.  222 
Several metabolic pathways were affected in preeclampsia; notably the taurine, glutamate and 223 
phospholipid metabolism. Taurine is an essential nutrient in fetal metabolism, as the fetus and 224 
placenta lack the enzyme for taurine synthesis [30]. Reduced activity of a placental taurine 225 




may impair syncytiotrophoblast cell renewal and lead to decreased nutrient transfer to the 227 
fetus [32]. In our study, taurine levels were similar in placentas from preeclampsia with or 228 
without FGR, suggesting that taurine depletion is not specific for FGR. Glutamine and 229 
glutamate are crucial to the fetal carbon and nitrogen metabolism as precursors to protein, 230 
purine and pyrimidine synthesis [33]. Glutamate is also a precursor to glutathione, an 231 
important antioxidant, and has been shown to be lower in medium of placental explants from 232 
hypoxic normal tissue and preeclamptic tissue [26]. Consistent with this finding, placental 233 
ascorbate was significantly lower in preeclamptic placentas. Intracellular ascorbate protects 234 
endothelial cells from apoptosis induced by hypoxia followed by reoxygenation, and may be 235 
depleted as a response to hypoxia [34].  236 
Two possible reasons for increased glycerophosphocholine in preeclampsia are suggested. 237 
First, the increase may be due to excessive cell death in preeclamptic placentas [35, 36]. This 238 
conforms to our findings of increased glycerophosphocholine especially in those pregnancies 239 
with increased maternal serum sFlt-1. Phosphatidylcholine catabolism releases 240 
glycerophosphocholine and arachidonic acid by the phospholipase PLA2, possibly playing a 241 
role in increased inflammation, a central process in the preeclamptic placenta. PLA2 activity is 242 
increased in preeclamptic placental tissue [37]. Second, the increase may stem from placental 243 
cell membrane catabolism for regeneration of choline methyl groups due to folate deficiency 244 
[38]. In our study, glycerophosphocholine was no longer significantly different between 245 
groups after adjustment for gestational age, as the metabolite decreases towards term in the 246 
preeclampsia group. The metabolite may still play a role in early onset disease. An MR 247 
imaging study of in utero placentas found increased placental phosphodiester components 248 
including glycerophosphocholine in early onset preeclampsia compared to gestational age 249 
matched controls [39], supporting that the increase is disease-related and not only dependent 250 




in this study similar in preeclamptic and normotensive placentas, indicating a compensatory 252 
mechanism. Another component of phospholipid biosynthesis, ethanolamine, was decreased 253 
in the preeclamptic placenta. Ethanolamine kinase deficient mice have low birth weight 254 
offspring and increased placental thrombosis and apoptosis, indicating an important role of 255 
ethanolamine in placental and fetal development [40]. An earlier metabolomics study using 256 
mass spectrometry of placental extracts found increased choline, succinate and 257 
glycerophosphocholine species in placentas from preeclamptic pregnancies [28], the two 258 
former of which we found no difference. However, many metabolites measured with MS are 259 
not observed in MRS spectra. 260 
The correlation of placental metabolic profiles to maternal serum sFlt-1 and triglycerides 261 
suggests that different placental phenotypes may be recognized by targeted measurements of 262 
maternal markers. Placental sampling must be done after delivery, but importantly, increased 263 
understanding of underlying placental disease components will enable a more targeted search 264 
for disease markers that more accurately reflect the diversity of the placental disease. 265 
Identification of a placental phenotype correlating to maternal serum markers is an important 266 
step in this direction. Novel markers reflecting the placental disease more directly will still 267 
need to be identified.  268 
Limitations of our study include the variation in GA between preeclamptic and normotensive 269 
pregnancies. Differences were accounted for using linear regression, but variation due to GA 270 
cannot easily be overcome in placenta research due to the nature of the preeclampsia 271 
diagnosis. Additionally, only one sample per placenta was analyzed, thus, intra-individual 272 
variability was not assessed. However, previous metabolomic analyses of the placenta found 273 
no or few spatial differences in metabolites [28, 41]. Finally, the time passed between CS and 274 




metabolic profiles may not directly reflect the in vivo situation  [41, 42]. Strengths of our 276 
study are the whole tissue profiling without need for extraction and derivatization, and the 277 
sensitivity as reflected by metabolite correlation to the placental derived stress factor sFlt-1 in 278 
maternal serum. All deliveries were by CS precluding any labor-induced variation. Sensitive 279 
placental profiling as shown here is missing from preeclampsia research. 280 
Metabolomics represents the closest measure to the phenotype, and this is reflected in the 281 
highly significant differences between placentas from normotensive and preeclamptic 282 
pregnancies. In this study we investigated pathways affected by preeclampsia, and found 283 
metabolic profiles specific for severe preeclampsia and correlating to increased maternal 284 
serum markers. An interesting direction of further research will be to metabolically classify 285 
the placental component of preeclampsia in larger cohorts, and identify unique factors that 286 
may benefit from separate treatments as has been done previously using gene expression 287 
analysis [43]. We present the HR-MAS MRS method as an excellent novel tool for placental 288 
disease phenotyping in pregnancy research possibly leading to future improved screening, 289 
prediction and follow-up of pregnant women at risk for preeclampsia. 290 
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Table 1: Clinical characteristics of study participants 
Variable Total PE (n=19) PE+FGR  
(n=11) 
PE severe (n=14) Normotensive 
(n=15) 
Maternal age in years, 
md (IQR) 
28 (9) 25 (6)*,*** 28 (10) 34 (5) 
Gravidity, md (IQR) 1 (2) 1 (2) 1 (2) 2 (1) 
Primipara, n (%) 9 (47.4)* 6 (54.5)* 7 (50.0) 2 (13.3) 
Systolic BP in mmHg, 
md (IQR)a 
160 (29)** 160 (30)** 170 (20)** 124 (20) 
Diastolic BP in mmHg, 
md (IQR)a 
100 (15)** 104 (11)** 105 (36)** 75 (11) 
BMI in kg/m2, md 
(IQR)b 
24.2 (13.0) 24.2 (13.4) 23.8 (11.1) 23.6 (4.5) 
CVD diagnosisc, n (%) 3 (15.8) 1 (9.1) 3 (21.4) 0 (0) 
GA at delivery in 
weeks, md [range] 
32.3 [25.6 -39.1] 31.7 [27.4-33.7] 32.3 [25.6-37.0] 39.3 [38.3 - 40.0] 
Birth weight in g, mn 
(SD) 
1707 (1074)** 1212 (342)** 1621 (785)** 3501 (309) 
Placental weight in g, 
md (IQR) 
300 (290)** 275 (125)** 295 (277)** 620 (150) 
FGR, n (%)d 11 (57.9)** 11 (100) 8 (57.1) 0 (0) 
Severe PE, n (%) 14 (73.7) 8 (72.7) 14 (100) 0 (0) 
Superimposed PE, n 
(%) 
2 (10.5) 1 (9.1) 2 (14.3) 0 
Early onset PE (<34 
weeks) n (%) 
17 (89.5) 11 (100) 13 (92.9) 0 (0) 
Gestational diabetes, n 
(%) 
2 (10.5) 0 (0) 2 (14.2) 0 (0) 
P values are from a one-way ANOVA with Tukey post-hoc test or the Kruskal Wallis test 
with post-hoc pairwise Mann-Whitney U tests. Categorical values were compared using 
Fishers exact test. 
a Blood pressure measured at the last regular prenatal visit, 0-2 weeks before cesarean section. 
b Maternal weight for BMI calculation was measured at the first prenatal care visit, before 
week 12 of pregnancy. Weight information was missing for one woman with severe PE and 
FGR, and one normotensive woman. 
c Pregestational CVD diagnoses included: pregestational hypertension, cardiomyopathies, 
congenital cardiac defects. 
d Birth weight <5th percentile according to fetal weight reference curves [11] was used as a 
proxy for one of the FGR diagnoses. 
* p<0.05 compared to normotensive. 
** p<0.001 compared to normotensive. 
*** p<0.05 compared to preeclampsia. 
Abbreviations: BMI; body mass index; BP; blood pressure; CVD, cardiovascular disease; 
GA; gestational age; FGR, fetal growth restriction; IQR; interquartile range; NA, not 
applicable; md; median; mn, mean; n, number; PE, preeclampsia; SD, standard deviation 
Table 2: Metabolite levels in placentas and maternal serum concentrations  
Metabolite, median (IQR) PE (n=19) Normotensive 
(n=15) 
P-value P (adj)a P (GA)b 
Phospholipid biosynthesis  
Ethanolamine 6.6 (1.3) 9.80 (3.1) <0.001 0.005 0.075 
Choline 75.5 (11.1) 74.7 (20.3) 0.864 0.891  
Glycerophosphocholine  22.5 (12.1) 13.2 (14.8) 0.007 0.018 0.344 
Phosphocholine 11.3 (5.6) 9.0 (4.5) 0.056 0.097  
Dihydroxyacetone 1.04 (1.25) 2.3 (1.9) 0.003 0.010 0.142 
Glycerol 25.9 (9.7) 25.9 (4.0) 0.945 0.945  
Myoinositol 16.8 (3.8) 16.5 (3.6) 0.811 0.863  
Ammonia recycling, Urea cycle, Bile acid biosynthesis  
Glutamine 5.4 (2.3) 7.6 (2.4) 0.004 0.013 0.029 
Aspartate 8.3 (4.4) 6.1 (2.4) 0.047 0.097  
Glutamate 16.4 (4.0) 21.7 (1.3 <0.001 0.005 <0.001 
Acetate 2.8 (1.1) 3.0 (0.8) 0.372 0.512  
Glycine 8.5 (2.5) 11.1 (2.0) 0.001 0.005 0.070 
Alanine  9.1 (3.4) 9.4 (3.0) 0.179 0.281  
Taurine 20.9 (7.5) 29.5 (4.6) <0.001 0.005 0.031 
Protein biosynthesis  
Leucine 11.23 (3.65) 11.77 (1.9) 0.286 0.410  
Isoleucine 1.8 (0.4) 2.0 (0.3) 0.056 0.097  
Valine 3.2 (0.8) 3.6 (0.9) 0.006 0.017 0.019 
Threonine 3.6 (1.1) 4.3 (0.7) 0.021 0.046 0.054 
Lysine 8.3 (3.5) 10.0 (0.9) 0.006 0.017 0.398 
Glycolysis, ketone body metabolism  
Lactate  42.2 (10.7) 41.9 (7.2) 0.391 0.515  
Glucose 2.5 (2.0) 3.3 (3.1) 0.111 0.183  
Succinate 3.0 (1.3) 3.7 (1.3) 0.056 0.097  
3-Hydroxybutyrate 2.7 (0.9) 4.4 (3.0) 0.019 0.045 0.023 
Catecholamine biosynthesis  
Ascorbate 2.2 (0.6) 2.9 (0.4) 0.001 0.005 0.045 
Glycine and serine metabolism  
Creatine 5.5 (1.9) 6.0 (1.9) 0.256 0.384  
Serum markers, median (IQR)c  
Cholesterol [mM] 6.8 (1.9) 6.1 (2.2) 0.580 0.660  
Creatinine [µM] 66.0 (20.0) 58.0 (9.0) 0.001 0.005  
Uric acid [µM] 399 (157) 279 (105) 0.002 0.008  
HDL [mM] 1.6 (0.4) 1.7 (0.5) 0.656 0.722  
Triglycerides [mM] 3.7 (2.4) 2.7 (1.1) 0.421 0.515  
Calcium [mM] 2.3 (0.3) 2.4 (0.2) 0.421 0.515  
hsCRP [µg mL-1] 4.8 (15.6) 3.3 (5.4) 0.486 0.573  
sFlt-1 [ng mL-1] 960 (1350) 239 (162) <0.001 0.005  
Metabolite levels are in arbitrary units relative to total spectral intensity. Metabolites and 
serum values were compared between preeclamptic and normotensive groups using the Mann-
Whitney U test. Metabolites grouped by metabolic pathways described in the small molecule 
pathway database [21]. The metabolites may be involved in several pathways. Abbreviations: 
GA, gestational age; HDL, high density lipoprotein; hsCRP, high sensitivity C-reactive 
protein; IQR, interquartile range; sFlt-1, soluble Fms-like tyrosine kinase receptor 1; PE, 
preeclampsia. 
a Corrected for multiple comparisons using the Benjamini-Hochberg false discovery rate. 
b Corrected for gestational age. Linear regression models were made with log transformed 
metabolite levels as dependent variable and gestational age as independent variable. The 
metabolite is then evaluated at the average values GA=245 days. 
c One placenta-serum pair was excluded due to missing blood sample. 
 
 
Table 3: PLS-DA results 
PLS-DA Model LVs Sens. Spec. Accuracy P-valuea Metabolites  
(Rel to 1st mentioned) 
Total PE (n=19) vs. 
normotensive (n=15) 
1 0.870 (0.863-0.877) 0.984 (0.973-0.996) 0.927 (0.912-0.934) <0.001 Increase: GPC, PCho, Asp 
Decrease: EtAm, Tau, Glu, Asc, Gly 
Severe PE (n=14) vs. 
non-severe PE (n=5) 
1 0.770 (0.707-0.832) 0.879 (0.859-0.897) 0.832 (0.802-0.862) 0.003 Increase: Cho, Lys, Ala, Glucose, 
Myo, Tau, Asp, Gln Decrease:  3-HB 
PE (n=8) vs. PE+FGR 
(n=11) 
1 0.631 (0.579-0.683) 0.723 (0.688-0.758) 0.677 (0.649-0.705) 0.163 Not significant 
Placental metabolic profiles were compared between groups using partial least squares discriminant analysis (PLS-DA), and the discriminatory 
ability assessed with 5-fold cross validation.  
a p value from 1000 permutation tests. 
Abbreviations: 3-HB, 3-hydroxybutyrate; Ala, alanine; Asc, ascorbate; Asp, aspartate; Cho, choline; EtAm, ethanolamine; FGR, fetal growth 
restriction; Gln, glutamine; Glu, glutamate; GPC, glycerophosphocholine; Gly, glycine; Lys, lysine; LVs, latent variables; Myo, myo-inositol; 
Tau, taurine; PCho, phosphocholine; PE, preeclampsia; PLS-DA, partial least squares discriminant analysis; rel, relative; sens, sensitivity;  sFlt-1, 
soluble fms-like tyrosine kinase receptor 1; spec, specificity;  Suc, succinate; Val, valine. 
 
Table 4: PLS results 
PLS regression 
Metabolites vs Y a 
LVs R2 b Y explained P-value c Metabolites 
Serum sFlt-1 1 0.482 (0.463-0.500) 0.614 <0.001 Increase: GPC 
Decrease: Glu, Tau, Gln, Val, EtAm, Suc 
Serum creatinine 1 0.102 (0.085-0.119) 0.343 0.032 Increase: GPC, Asp, PCho, Cre 
Decrease: Gly, EtAm 
Serum uric acid 1 0.128 (0.110-0.147) 0.348 0.009 Increase: Asp, GPC 
Decrease: Glu, Tau, Gln, Val, EtAm, Suc 
Serum triglycerides 2 0.164 (0.130-0.198) 0.166 <0.001 Increase: Cho, Gln, Gly 
Decrease: 3-HB, Cre 
Results from partial least squares regression for correlation between metabolic placenta profiles and maternal serum measurements. The maternal 
serum values are for 33 placenta/serum pairs (34 placentas - 1 excluded from serum measurements due to missing blood sample). Results were 
assessed with 5-fold cross validation.  
a Y denotes the dependent variable, e.g, the serum measurement  
bR2 values give the correlation of the cross-validated predicted Y values to the real Y values.  
c p value from 1000 permutation tests. 
Abbreviations: 3-HB, 3-hydroxybutyrate; Asp, aspartate; Cho, choline; Cre, creatine  EtAm, ethanolamine; Gln, glutamine; Glu, glutamate; GPC, 
glycerophosphocholine; Gly, glycine;  LVs, latent variables; Tau, taurine; PCho, phosphocholine; PLS; partial least squares regression; sFlt-1, 
soluble Fms-like tyrosine kinase receptor 1; Suc, succinate; Val, valine.  
 
Supplementary	information	
(See Supplementary tables 1 and 2 in separate documents). 
Table S.3  
Identified metabolites in 1H and 1H-13C nuclear magnetic resonance (NMR) spectra of placental 
biopsies (n=34). 
Metabolite name NMR shifts, 1H (13C) 
3-Hydroxybutyrate 1.197d 
Acetate 1.927s (26.9) 
Alanine 1.478d (19.0), 3.779q (53.4) 
Ascorbic acid 4.515s 
Aspartic acid 2.818dd (39.5) 
Choline 3.207s (56.7), 3.527t (70.4), 4.051b (58.5) 
Creatine 3.029s (41.8), 3.937s  
Dihydroxyacetone 4.417s 
Ethanolamine 3.135t/dd(44.3), 3.82d (61.1) 
Glucose 3.269t (77.14), 3.394m (72.4), 3.468m (78.8), 3.521m (74.3), 
3.898m (63.5), 4.652d (97.8) 
Glutamic acid 2.055m (27.4), 2.338m (36.4), 3.759t (57.0) 
Glutamine 2.138m (27.4), 2.444m (35.9) 
Glycerol 3.650dd (65.4), 3.780m (74.9) 
Glycerophosphocholine 3.234s (56.7), 4.33m (62.0) 
Glycine 3.650s (53.6) 
Isoleucine 0.955t, 1.003d 
Lactic acid 1.318d (23.0), 4.123q (71.3) 
Leucine 0.967d 
Lysine 1.718quin 1.902m, 3.021t (42.2) 
Myoinositol 3.27t (77.1), 3.556dd (74.2), 3.620t (75.1) 
Phosphocholine 3.222s (56.7) 
Succinic acid 2.410s (36.8) 
Taurine 3.263t (50.9), 3.423t (38.2) 
Threonine 1.318d (23.0), 3.586d (65), 4.255m (69.4) 
Valine 0.988d, 1.042d (20.42) 
Multiplicity of peaks are given as follows: s, singlet; d, doublet; t, triplet; q, quartet, quin, 
quintet; dd, doublet of doublet; m, multiplet.  
  
Table S.4 
Metabolite Set Enrichment Analysis of quantitative metabolite data from placenta from women 
with preeclampsia (n=19) and normotensive pregnancies (n=15). 
Pathway Total Cmpda 
Hitsb Q  Statisticc  Expected Qd Raw pe FDRf 
Bile acid biosynthesis 49 2 39.30 3.03 1.90	x	10-7 6.07E-06 
Taurine and hypotaurine 
metabolism 
7 1 51.60 3.03 1.72	x	10-6 2.76	x	10-5 
Phospholipid 
biosynthesis 
19 2 29.17 3.03 6.07	x	10-6 6.47	x	10-5 
Ammonia recycling 18 3 21.32 3.03 2.82	x	10-5 2.25	x	10-4 
Protein biosynthesies 19 6 15.75 3.03 1.44	x	10-4 9.24	x	10-4 
Urea cycle 20 2 18.48 3.03 9.32	x	10-4 0.005 
Glutathione metabolism 10 1 26.99 3.03 0.002 0.007 
Porphyrin metabolism 22 1 26.99 3.03 0.002 0.007 
Pyrimidine metabolism 36 1 25.47 3.03 0.002 0.007 
Purine metabolism 45 1 25.471 3.03 0.002 0.007 
Glycine, serine and 
threonine metabolism 
26 3 13.69 3.03 0.003 0.007 
Propanoate metabolism 18 1 24.97 3.03 0.003 0.007 
Glutamate metabolism 18 2 17.69 3.03 0.009 0.022 
Methionine metabolism 24 2 13.50 3.03 0.010 0.024 
Valine, leucine and 
isoleucine degradation 
36 2 14.90 3.03 0.016 0.033 
Lysine degradation 13 1 13.93 3.03 0.030 0.056 
Biotin metabolism 4 1 13.93 3.03 0.030 0.056 
Beta-alanine metabolism 13 1 11.49 3.03 0.050 0.080 
Aspartate metabolism 12 1 11.49 3.03 0.050 0.080 
Malate-aspartate shuttle 8 1 11.49 3.03 0.050 0.080 
Citric acid cycle 23 1 9.90 3.03 0.070 0.102 
Mitochondrial electron 
transport chain 
15 1 9.90 3.03 0.070 0.102 
Metabolite set enrichment analysis results (Performed on Metaboanalyst online, 
www.metaboanalyst.ca  [1]).   
a Total number of compounds (metabolites) in the pathway 
b  Number of measured metabolites found in pathway 
c Q-statistic describing the correlation between compound concentration profiles and phenotype 
labels 
d Expected Q statistic given no correlation between compounds and phenotype labels 
e P value for the probability of obtaining the Q statistic 
f P values corrected for multiple correction using false discovery rates 
  
Table S.7 










Ethanolamine 6.6 (3.8) 6.7 (1.2) 0.964 1.000 
Choline 67.7 (18.2) 78.1 (7.4) 0.003 0.038* 
Glycerophosphocholine  21.3 (20.8) 23.1 (16.02) 1.000 1.000 
Phosphocholine 8.0 (8.3) 11.4 (4.2) 0.931 1.000 
Dihydroxyacetone 1.0 (0.7) 1.1 (1.4) 0.559 0.736 
Glycerol 20.9 (16.9) 25.9 (7.1) 0.500 0.694 
Myoinositol 13.3 (6.4) 17.0 (2.0) 0.107 0.243 
Ammonia recycling, urea cycle, bile acid biosynthesis 
Glutamine 4.8 (2.0) 5.6 (2.5) 0.070 0.242 
Aspartate 6.8 (12.7) 8.3 (4.6) 0.687 0.818 
Glutamate 13.8 (4.3) 17.0 (3.4) 0.044 0.242 
Acetate 2.6 (1.7) 2.8 (1.0) 0.444 0.653 
Glycine 7.3 (2.5) 8.8 (2.1) 0.219 0.391 
Alanine  6.3 (3.4) 9.7 (2.0) 0.056 0.242 
Taurine 18.0 (7.3) 21.9 (6.1) 0.130 0.271 
Protein biosynthesis 
Leucine 9.0 (2.5) 11.6 (3.1) 0.087 0.242 
Isoleucine 1.6 (0.4) 1.8 (0.5) 0.257 0.402 
Valine 3.0 (0.3) 3.5 (0.7) 0.107 0.243 
Threonine 2.9 (1.0) 3.8 (0.7) 0.070 0.242 
Lysine 5.9 (1.5) 9.1 (3.8) 0.003 0.038* 
Glycolysis, ketone body metabolism 
Succinate 2.7 (1.9) 3.1 (1.2) 0.257 0.402 
Lactate  42.2 (7.7) 41.3 (11.1) 0.823 0.935 
Glucose 1.6 (1.0) 2.8 (1.6) 0.034 0.242 
3-Hydroxybutyrate 3.2 (2.0) 2.7 (0.8) 0.186 0.358 
Catecholamine biosynthesis 
Ascorbate 1.9 (0.9) 2.3 (0.6) 0.087 0.242 
Glycine and serine metabolism 
Creatine 5.7 (5.1) 5.3 (2.2) 0.687 0.818 
Metabolites were compared between groups using the Mann-Whitney U test. Metabolites 
grouped by metabolic pathways described in the small molecule pathway database [2]. The 
metabolites may be involved in several pathways. Metabolite levels are in arbitrary units relative 
to total spectral intensity.  
Abbreviations: FDR, false discovery rate; IQR, interquartile range; PE, preeclampsia. 
a Corrected for multiple comparisons using the Benjamini-Hochberg false discovery rate. 




Comparison between metabolite levels in placentas from women with preeclamptic and 
normotensive pregnancies, with adjustments for gestational age. 
Metabolite P a 
(PE vs Normotensive) 
P  
(adjusted for GA) 
Ethanolamine 0.005 0.075 
Glycerophosphocholine 0.018 0.344 
Dihydroxyacetone 0.011 0.142 
Glutamine 0.013 0.029* 
Glutamate 0.005 <0.001* 
Glycine 0.005 0.070 
Taurine 0.005 0.031* 
Valine 0.017 0.019* 
Lysine 0.017 0.398 
Threonine 0.046 0.054 
3-HB 0.045 0.023* 
Ascorbate 0.005 0.045* 
For preeclamptic vs normotensive groups, the Mann-Whitney U test (adjusted for multiple 
comparisons) is given. For the gestational age adjusted p values, linear regression models were 
made with log transformed metabolite levels as dependent variable and gestational age as 
independent variable. The metabolite is then evaluated at the average values GA=245 days. 
Abbreviations: 3HB, three-hydroxybutyrate; GA, gestational age; PE, preeclampsia. 
a Adjusted for multiple comparisons using the Benjamini-Hochberg false discovery rate for all 
tested metabolites. 
* Significantly different between normotensive and preeclamptic placentas after correction for 
difference in gestational age. 
 
Figure S.1. Receiver-operator characteristic curves for prediction of class from metabolic profile 
of the placenta. a) Discrimination of preeclampsia from normotensive. b) Discrimination of 
severe preeclampsia from non-severe preeclampsia. c) Discrimination of preeclampsia with fetal 
growth restriction from preeclampsia without fetal growth restriction. d) Results from 
permutation testing showing true vs. permuted classification accuracy for the three classification 
models.  
Abbreviations: FGR, fetal growth restriction; non-sev., non-severe; PE, preeclampsia, ROC, 
receiver-operator characteristic. 
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